Merck & Company Inc (MRK)vsDentsply Sirona Inc (XRAY)
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
XRAY
Dentsply Sirona Inc
$10.00
+1.21%
HEALTHCARE · Cap: $2.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1687% more annual revenue ($65.77B vs $3.68B). MRK leads profitability with a 13.6% profit margin vs -17.1%. XRAY appears more attractively valued with a PEG of 0.74. XRAY earns a higher WallStSmart Score of 54/100 (C-).
MRK
Hold50
out of 100
Grade: D+
XRAY
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
+70.6%
Fair Value
$46.69
Current Price
$10.00
$36.69 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.1% revenue growth
Operating margin of 3.4%
Elevated debt levels
ROE of -37.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : XRAY
The strongest argument for XRAY centers on Price/Book, PEG Ratio. PEG of 0.74 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : XRAY
The primary concerns for XRAY are Revenue Growth, Operating Margin, Debt/Equity. Debt-to-equity of 1.77 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while XRAY is a turnaround play — different risk/reward profiles.
XRAY carries more volatility with a beta of 0.94 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
XRAY scores higher overall (54/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Dentsply Sirona Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Dentsply Sirona is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?